Payment overview · 2025
General Payments
$2,016.45
68 reported records · 21 companies
Healthcare provider profile · identity verified
Wei K Kao, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RONKONKOMA, NY · NPI 1629295571
Verified facts
What the public records show
CMS Open Payments records show Wei K Kao, M.D. received $2,016.45 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Linzess, Lokelma, Mounjaro, Nexletol, Otezla, Ozempic, Rexulti, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Otezla by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rytary by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 722 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $466.99 | 23.2% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $343.74 | 17.1% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $186.29 | 9.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.71 | 8.0% | 6 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$139.36 | 6.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.18 | 5.1% | 5 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $75.48 | 3.7% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $73.92 | 3.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.84 | 3.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.48 | 3.4% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.72 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.86 | 2.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.61 | 2.2% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.67 | 1.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.93 | 1.3% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.57 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.38 | 1.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.00 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.83 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.61 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.28 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,016.45 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $367.12 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $209.56 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $181.20 | 8 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $139.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.19 | 4 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $117.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.94 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.94 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.88 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $75.48 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $73.92 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $67.48 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $61.72 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.34 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.10 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $45.86 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.19 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 125 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 722 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 102 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 29 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
125 | 125 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
722 | 126 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1396 | 347 |
| Levothyroxine Sodium | Levothyroxine Sodium | 995 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 772 | 217 |
| Metoprolol Succinate | Metoprolol Succinate | 728 | 199 |
| Eliquis | Apixaban | 722 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 648 | 217 |
| Furosemide | Furosemide | 641 | 167 |
| Potassium Chloride | Potassium Chloride | 511 | 132 |
| Tamsulosin Hcl | Tamsulosin Hcl | 487 | 137 |
| Omeprazole | Omeprazole | 456 | 145 |
| Metformin Hcl | Metformin Hcl | 443 | 112 |
| Gabapentin | Gabapentin | 414 | 108 |
| Metoprolol Tartrate | Metoprolol Tartrate | 410 | 123 |
| Lisinopril | Lisinopril | 391 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 389 | 113 |
| Famotidine | Famotidine | 382 | 85 |
| Losartan Potassium | Losartan Potassium | 375 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 353 | 116 |
| Sertraline Hcl | Sertraline Hcl | 329 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 279 | 73 |
| Simvastatin | Simvastatin | 236 | 63 |
| Ezetimibe | Ezetimibe | 234 | 73 |
| Carvedilol | Carvedilol | 219 | 60 |
| Sodium Chloride | 0.9 % Sodium Chloride | 215 | 94 |
| Levetiracetam | Levetiracetam | 212 | 43 |
| Warfarin Sodium | Warfarin Sodium | 211 | 35 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 205 | 28 |
| Donepezil Hcl | Donepezil Hcl | 204 | 60 |
| Mirtazapine | Mirtazapine | 169 | 51 |
| Prednisone | Prednisone | 168 | 105 |
| Finasteride | Finasteride | 167 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 58 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 155 | 80 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 39 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 149 | 73 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 148 | 43 |
| Nystatin | Nystatin | 147 | 60 |
| Memantine Hcl | Memantine Hcl | 142 | 37 |
| Torsemide | Torsemide | 142 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 39 |
| Atenolol | Atenolol | 137 | 35 |
| Montelukast Sodium | Montelukast Sodium | 137 | 51 |
| Trazodone Hcl | Trazodone Hcl | 131 | 44 |
| Valsartan | Valsartan | 131 | 42 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 125 | 125 |
| Allopurinol | Allopurinol | 125 | 38 |
| Spironolactone | Spironolactone | 123 | 35 |
| Alprazolam | Alprazolam | 122 | 62 |
| Gemtesa | Vibegron | 122 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 121 | 24 |
| Buspirone Hcl | Buspirone Hcl | 119 | 32 |
| Divalproex Sodium | Divalproex Sodium | 117 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 63 |
| Meloxicam | Meloxicam | 109 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 108 | 31 |
| Farxiga | Dapagliflozin Propanediol | 102 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 101 | 31 |
| Mupirocin | Mupirocin | 94 | 47 |
| Midodrine Hcl | Midodrine Hcl | 89 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 74 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 87 | 19 |
| Glimepiride | Glimepiride | 86 | 30 |
| Synthroid | Levothyroxine Sodium | 84 | 29 |
| Enalapril Maleate | Enalapril Maleate | 82 | 21 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 78 | 38 |
| Metformin Hcl Er | Metformin Hcl | 77 | 23 |
| Azithromycin | Azithromycin | 75 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 24 |
| Ozempic | Semaglutide | 73 | 26 |
| Risperidone | Risperidone | 73 | 22 |
| Vascepa | Icosapent Ethyl | 72 | 12 |
| Entresto | Sacubitril/Valsartan | 71 | 16 |
| Bupropion Xl | Bupropion Hcl | 70 | 21 |
| Nystop | Nystatin | 67 | 34 |
| Gemfibrozil | Gemfibrozil | 66 | 21 |
| Mounjaro | Tirzepatide | 66 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 14 |
| Santyl | Collagenase Clostridium Hist. | 65 | 30 |
| Baclofen | Baclofen | 64 | 22 |
| Lactulose | Lactulose | 63 | 25 |
| Ssd | Silver Sulfadiazine | 63 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 58 | 18 |
| Fluocinonide | Fluocinonide | 58 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 22 |
| Xarelto | Rivaroxaban | 56 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 54 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 15 |
| Ceftriaxone | Ceftriaxone Sodium | 53 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 43 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | 15 |
| Latanoprost | Latanoprost | 51 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 45 |
| Dextrose In Water | Dextrose 5 % In Water | 50 | 28 |
| Jardiance | Empagliflozin | 50 | 17 |
| Ramipril | Ramipril | 50 | 14 |
| Alendronate Sodium | Alendronate Sodium | 49 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 40 |
| Ertapenem | Ertapenem Sodium | 48 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 35 |
| Glipizide | Glipizide | 47 | 15 |
| Methocarbamol | Methocarbamol | 47 | 23 |
| Nifedipine Er | Nifedipine | 47 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 11 |
| Retacrit | Epoetin Alfa-Epbx | 46 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 45 | 18 |
| Permethrin | Permethrin | 45 | 20 |
| Scopolamine | Scopolamine | 45 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 43 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 41 | 25 |
| Azelastine Hcl | Azelastine Hcl | 41 | suppressed |
| Desloratadine | Desloratadine | 41 | suppressed |
| Linzess | Linaclotide | 41 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Fluconazole | Fluconazole | 39 | 24 |
| Heparin Sodium | Heparin Sodium,porcine | 39 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 39 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 18 |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 13 |
| Ketoconazole | Ketoconazole | 36 | 25 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 36 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 35 | 31 |
| Enoxaparin Sodium | Enoxaparin Sodium | 35 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 31 | 12 |
| Silver Sulfadiazine | Silver Sulfadiazine | 31 | 26 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 30 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Digoxin | Digoxin | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | 11 |
| Sucralfate | Sucralfate | 28 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | 13 |
| Dexamethasone | Dexamethasone | 26 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 19 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 21 |
| Haloperidol | Haloperidol | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 16 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 25 | 24 |
| Otezla | Apremilast | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Calcipotriene | Calcipotriene | 23 | suppressed |
| Daptomycin | Daptomycin | 23 | suppressed |
| Nyamyc | Nystatin | 23 | 11 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 23 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Procrit | Epoetin Alfa | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | 13 |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 15 |
| Topiramate | Topiramate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ivermectin | Ivermectin | 17 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 12 |
| Lorazepam | Lorazepam | 17 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 17 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Klayesta | Nystatin | 15 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Meropenem | Meropenem | 13 | 12 |
| Metronidazole | Metronidazole | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Zosyn | Piperacillin-Tazo-Dextrose,iso | 12 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Clindamycin Phosphate-D5w | Clindamycin Phosphate/D5w | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,016.45 · 68 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, IBSRELA, INSPIRE, ISTURISA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, LOKELMA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PERCEPT PC BRAINSENSE, PREVNAR 20, REPATHA, REXULTI, UNITHROID, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error